Ongoing results of a phase 1B/2 dose-escalation and cohort-expansion study of the selective, noncovalent, reversible Bruton's tyrosine kinase inhibitor, vecabrutinib, in B-cell malignancies Meeting Abstract
| Authors: | Allan, J. N.; Patel, K.; Mato, A. R.; Wierda, W. G.; Pinilla Ibarz, J.; Choi, M. Y.; O'Brien, S. M.; Sharman, J. P.; Shadman, M.; Gladstone, D. E.; Davids, M. S.; Pagel, J. M.; Ward, R.; Acton, G.; Taverna, P.; Fox, J. A.; Furman, R. R.; Brown, J. R. |
| Abstract Title: | Ongoing results of a phase 1B/2 dose-escalation and cohort-expansion study of the selective, noncovalent, reversible Bruton's tyrosine kinase inhibitor, vecabrutinib, in B-cell malignancies |
| Meeting Title: | 61st Annual Meeting and Exposition of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 134 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2019 Dec 7-10 |
| Meeting Location: | Orlando, FL |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2019-11-13 |
| Language: | English |
| ACCESSION: | WOS:000577160407166 |
| DOI: | 10.1182/blood-2019-126286 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 3041 -- Source: Wos |
